BOSTON--(

波士顿--(

BUSINESS WIRE

BUSINESS WIRE

)--Ypsilon Therapeutics, a portfolio company of 82VS, Alloy’s venture studio, has been awarded $2.7 million in seed funding from CPRIT. Ypsilon will use the grant to rapidly advance its lead therapeutic program, a next generation T-cell receptor mimic (TCRm) antibody, to drug candidate nomination, furthering its mission to deliver breakthrough treatments for patients with difficult to treat solid tumors such as triple negative breast cancer, non-small cell lung cancer, and gastric cancer.

)--Ypsilon Therapeutics是Alloy的风险投资工作室82VS的投资组合公司，已从CPRIT获得270万美元的种子资金。Ypsilon将利用这笔资金迅速推进其领先治疗计划，即下一代T细胞受体模拟物（TCRm）抗体，以获得候选药物提名，进一步推动其为难治性实体瘤患者（如三阴性乳腺癌，非小细胞肺癌和胃癌）提供突破性治疗的使命。

Ypsilon’s CPRIT grant, one of nine awards selected from 90 applicants, will also fund the critical establishment of the company’s operations in Texas..

Ypsilon的CPRIT赠款是从90名申请人中选出的9个奖项之一，它还将为该公司在德克萨斯州的关键业务提供资金。

TCRms are an emerging class of antibody-based drugs that have been engineered to bind with high specificity to intracellular protein fragments presented on the surface of cells by major histocompatibility complex molecules (pMHC). Compared to traditional antibodies that only target soluble or cell surface proteins, TCRms enable targeting of an expanded set of intracellular proteins including cancer testes antigens and other oncogenic drivers that are highly specific to tumor cells.

TCRM是一类新兴的基于抗体的药物，已被设计为以高特异性结合主要组织相容性复合物分子（pMHC）在细胞表面呈递的细胞内蛋白质片段。与仅靶向可溶性或细胞表面蛋白的传统抗体相比，TCRM能够靶向一组扩展的细胞内蛋白，包括癌症睾丸抗原和其他对肿瘤细胞高度特异的致癌驱动因子。

Ypsilon is developing bispecific T cell engager molecules that can bind tumor associated pMHC complexes and drive potent cell killing..

Ypsilon正在开发双特异性T细胞参与分子，可以结合肿瘤相关的pMHC复合物并驱动有效的细胞杀伤。

“We founded Ypsilon to leverage the incredible specificity of how TCRs interact with proteins on the surface of cancer cells to enable new ways to target and treat cancer with high precision and efficacy,” said Dr. Dongxing Zha, CEO/Co-Founder of Ypsilon and CTO of TCR Discovery and Engineering at Alloy.

Ypsilon首席执行官/联合创始人兼Alloy TCR Discovery and Engineering首席技术官ZhaDongxing博士表示：“我们成立Ypsilon是为了利用TCR与癌细胞表面蛋白质相互作用的难以置信的特异性，从而实现以高精度和有效性靶向和治疗癌症的新方法。”

“The award from CPRIT will allow us to advance our lead TCRm program to drug candidate nomination and support our move to Texas, where I spent seven years of my career at the MD Anderson Cancer Center. I look forward to further contributing to the growth and success of the Texas biotech community.”.

“CPRIT的奖项将使我们能够推动我们的主要TCRm计划获得候选药物提名，并支持我们前往德克萨斯州，我在那里的MD安德森癌症中心度过了七年的职业生涯。我期待着为德克萨斯州生物技术社区的成长和成功做出进一步贡献。”

Ypsilon’s innovative TCRm programs leverage Alloy’s

Ypsilon的创新TCRm计划利用了Alloy

Keyway™ TCR Discovery platform,

Keyway™TCR发现平台，

which was developed by Dr. Zha. Alloy’s Keyway TCR Discovery platform is the first fully-integrated service offering to unlock the therapeutic potential of a variety of T-cell receptor-based modalities. Keyway’s end-to-end TCRm discovery service includes pMHC production, antibody discovery in Alloy’s suite of transgenic humanized mice, specificity screening, and generation of optimized T cell engagers.

这是由Zha博士开发的。Alloy的Keyway TCR发现平台是第一个完全集成的服务，可以释放各种基于T细胞受体的模式的治疗潜力。Keyway的端到端TCRm发现服务包括pMHC生产，Alloy转基因人源化小鼠套件中的抗体发现，特异性筛选以及优化T细胞参与者的产生。

“The CPRIT grant is a significant endorsement of Ypsilon’s approach to developing novel cancer therapeutics and highlights 82VS’s ability to identify and launch companies with strong potential to secure external funding,” said Errik Anderson, CEO and Founder of Alloy Therapeutics and General Partner at 82VS.

82VS Alloy therapeutics首席执行官兼创始人兼普通合伙人埃里克·安德森（Errik Anderson）表示：“CPRIT赠款是对Ypsilon开发新型癌症治疗方法的重大认可，并突出了82VS识别和启动具有强大潜力的公司以获得外部资金的能力。”

“Ypsilon is leveraging the Keyway platform within Alloy, showcasing our commitment to democratizing access to advanced biologics discovery services and cutting-edge technologies. We’re confident that Ypsilon’s move to Texas will not only strengthen the state’s world-class biomedical community, but also enhance our ability to discover and support promising Texas-based companies through the 82VS portfolio.”.

“Ypsilon正在利用Alloy内的Keyway平台，展示我们对先进生物制剂发现服务和尖端技术民主化的承诺。我们相信Ypsilon迁往德克萨斯州不仅会加强该州的世界级生物医学社区，而且还会增强我们通过82VS投资组合发现和支持有前途的德克萨斯州公司的能力。”。

About 82VS

关于82VS

82VS is the venture studio of Alloy Therapeutics, empowering exceptional scientist-entrepreneurs building therapeutic drug companies leveraging Alloy’s platforms and services. Aligned with the collaborative ecosystem ethos at Alloy, 82VS looks to partner and collaborate at every stage of the process supporting teams from ideation through to company creation, discovery, financing, and scaling of their businesses..

82VS是Alloy Therapeutics的风险工作室，授权杰出的科学家企业家利用Alloy的平台和服务建立治疗药物公司。与Alloy的合作生态系统精神相一致，82VS希望在流程的每个阶段进行合作和协作，支持团队从构思到公司创建、发现、融资和扩大业务规模。

About Alloy Therapeutics

关于Alloy Therapeutics

Alloy Therapeutics, Inc. is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners across academia, biotech, and the largest biopharma, Alloy democratizes access to pre-competitive tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics across six modalities: antibodies, TCRs, genetic medicines, peptides, cell therapies, and drug delivery.

Alloy Therapeutics，Inc.是一家生物技术生态系统公司，授权全球科学界共同生产更好的药物。通过学术界、生物技术界和最大的生物制药界的合作伙伴社区，Alloy将竞争前工具、技术、服务和公司创建能力的获取民主化，这些能力是发现和开发六种治疗性生物制剂的基础：抗体、TCR、基因药物、肽、细胞疗法和药物输送。

Partners may access all current and future technologies through a discovery service relationship or for a flat fee through Alloy’s Innovation Subscriptions offering. As a reflection of Alloy’s relentless commitment to the scientific community, Alloy reinvests 100% of its revenue in innovation and access to innovation..

合作伙伴可以通过发现服务关系或通过Alloy的创新订阅服务获得所有当前和未来的技术。Alloy将其收入的100%用于创新和获取创新，这反映了Alloy对科学界的不懈承诺。

Join the Alloy Therapeutics community by visiting

访问Alloy Therapeutics社区

alloytx.com

alloytx.com

About CPRIT

关于CPRIT

CPRIT was established in 2007 by the Texas Legislature with a three-part mission to invest in the research prowess of Texas universities and research organizations; create and expand life science infrastructure across the state; and expedite innovation in research and enhance the potential of breakthroughs in prevention and cures.

CPRIT于2007年由德克萨斯州议会成立，其使命分为三部分，旨在投资德克萨斯大学和研究组织的研究能力；在全州范围内创建和扩展生命科学基础设施；加快研究创新，增强防治突破潜力。

As a $6 billion initiative, it is the largest state cancer research investment in the history of the United States and the second-largest cancer research and prevention program in the world..

作为一项60亿美元的计划，它是美国历史上最大的州立癌症研究投资，也是世界第二大癌症研究和预防计划。